Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
CellCentric Ltd.
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Prelude Therapeutics
Celgene
Celgene